Related Experiment Video
Updated: Aug 9, 2026
10:39
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
The nitroxide Tempol modulates anthracycline resistance in breast cancer cells
Marzia B Gariboldi1, Francesca Terni, Raffaella Ravizza
1DBSF, University of Insubria, Busto Arsizio, Varese, Italy.
Free Radical Biology & Medicine
|April 25, 2006
Summary
Tempol (TPL) enhances doxorubicin (DOX) chemotherapy effectiveness against multidrug-resistant (MDR) breast cancer. TPL increases DOX accumulation and affects key proteins, offering a potential strategy to overcome drug resistance.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Multidrug resistance (MDR) significantly hinders anthracycline chemotherapy efficacy.
- Doxorubicin (DOX) is a key anthracycline agent used in cancer treatment.
- Overcoming MDR is crucial for improving patient outcomes in breast cancer.
Purpose of the Study:
- To investigate the effects of Tempol (TPL) on MDR mechanisms in human breast adenocarcinoma cells.
- To evaluate the synergistic potential of TPL combined with DOX in overcoming doxorubicin resistance.
- To elucidate the molecular pathways through which TPL influences drug resistance.
Main Methods:
- Cytotoxicity assays were performed on MCF-7 wildtype and MCF-7 Adr(R) MDR cells.
- Cellular peroxide levels and glutathione pools were measured.
- Doxorubicin accumulation was assessed using flow cytometry and specific antibodies for P-glycoprotein.
- Expression levels of proteins like p53, bcl2, bax, and p21 were analyzed.
Main Results:
- Tempol (TPL) exhibited a synergistic effect with doxorubicin (DOX) in MCF-7 Adr(R) cells when administered before or simultaneously with DOX.
- TPL increased intracellular peroxide levels and depleted cellular glutathione.
- TPL enhanced DOX accumulation by inhibiting P-glycoprotein-mediated efflux.
- TPL modulated the expression of proteins involved in drug response, including p53, bcl2, bax, and p21.
Conclusions:
- Tempol (TPL) demonstrates potential as an adjuvant agent to enhance doxorubicin (DOX) efficacy in multidrug-resistant (MDR) breast cancers.
- TPL's mechanisms include increasing oxidative stress, depleting glutathione, and inhibiting P-glycoprotein.
- Further investigation into TPL as a strategy to overcome MDR in clinical settings is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...